Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Corcept Therapeutics Incorporated
CORT
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.5B
$89.06
▲ +0.65%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$28.66 - $91.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 24.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary cortisol-modulating technology platform
- First-mover advantage in selective cortisol modulation for multiple rare diseases
- Strong intellectual property portfolio protecting key pipeline candidates
- Clinical expertise in managing severe endocrine and metabolic disorders
Bear Case
2 risks
- Low volatility (beta 0.5).
- Premium valuation to Biotech & Therapeutics peers
Growth
Strong growth ahead
Expanding Korlym market penetration and label expansion
Value
Premium valuation to Biotech & Therapeutics peers
Momentum
Hot
+108.2% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying CORT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 30, 2026
APR 30, 2026
Reported EPS of -$0.30 vs -$0.11 consensus (-176.5% surprise). Revenue of $164.9M vs $185.8M expected (-11.3%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-176.5%
Next: Jul 30, 2026
Revenue trend · last 8Q
—
—
—
—
+19%
+14%
+11%
+5%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$163.8M
$182.5M
$181.9M
$157.2M
$194.4M
$207.6M
$202.1M
$164.9M
Margins · last 8Q
Gross
98.3%
Operating
-30.1%
Profit
-18.9%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
$88.00
▼ -1.2% vs $89.06
Latest: HC Wainwright · $95.00 · Jun 2, 2026
3 analysts covering